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Summary
Background: Drug-eluting stents (DES) have signiﬁcantly reduced in-stent restenosis. But the
calciﬁcation of coronary artery lesions in hemodialysis patients is a high-risk factor for restenosis
after DES implantation. We hypothesized that percutaneous transluminal coronary rotational
atherectomy (PTCRA) may be useful in the prevention of underexpansion and fracture of the
stents, thereby reducing major adverse cardiac events.
Methods: We retrospectively compared the primary success and mid-term outcomes (major
adverse cardiac events within 12 months) of hemodialysis patients with calciﬁed coronary
lesions undergoing DES implantation using PTCRA (n = 26) with those where DES was implanted
without PTCRA (n = 28).
Results: The rates of target lesion revascularization in the PTCRA group were lower than those
in the non-PTCRA group (11.5% vs 35.7%, p = 0.026). The rates of restenosis and subacute throm-
bosis in the PTCRA group were modestly lower than those in the non-PTCRA group (restenosis
rate, 17.4% vs 17.4%, p = 0.061; subacute thrombosis rate, 0% vs 7.1%, p = 0.31).
Conclusion: PTCRA may be useful for improving the mid-term outcome of DES implantation in
hemodialysis patients with calciﬁed lesions.
© 2009 Published by Elsevier Ireland Ltd on behalf of Japanese College of Cardiology.∗ Corresponding author at: Department of Cardiovascular Center
edicine, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo
05-8470, Japan. Tel.: +81 3 3588 1111x7185; fax: +81 3 3582 7068.
E-mail address: hafujimoto-circ@umin.ac.jp (H. Fujimoto).
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oi:10.1016/j.jjcc.2009.11.003ackgroundrug-eluting stents (DESs) have reduced the rates of in-
tent restenosis (ISR) and target lesion revascularization
TLR) compared with bare metal stents [1,2]. Hemodial-
sis (HD) and severe calciﬁcation of coronary lesions are
igh-risk factors for restenosis after DES implantation
on behalf of Japanese College of Cardiology.
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(Figure 1 Calciﬁed lesions. Calciﬁed lesions were deﬁned as t
cation by coronary angiography. (A) Circular calciﬁcation of righ
artery.
[3—7]. Many factors are thought to contribute to resteno-
sis after DES implantation in HD patients; among them,
underexpansion and fracture of stents may be closely
related to ISR. We hypothesized that percutaneous trans-
luminal coronary rotational atherectomy (PTCRA) may be
useful for the prevention of underexpansion and frac-
ture of stents, thereby reducing major adverse cardiac
events after DES implantation in the calciﬁed lesions of HD
patients.
In this study, we retrospectively compared the primary
and mid-term outcomes of HD patients with calciﬁed coro-
nary lesions undergoing DES implantation using PTCRA with
those where DES was implanted without PTCRA.
Methods
Subjects
From July 2004 to December 2008, 74 consecutive patients
with chronic renal failure on HD underwent DES implantation
in our hospital. Among the 74 patients, 54 were diagnosed
to have 54 lesions with severe calciﬁcation. Calciﬁed lesions
were deﬁned as those in which we could detect circular
calciﬁcation or bulky calciﬁcation by coronary angiography
(CAG) (Fig. 1). Among the 54 patients with calciﬁed lesions,
26 underwent DES implantation using PTCRA, and 28 had
DES implanted without PTCRA. PTCRA was not performed
in the latter 28 patients mainly because of the restriction
of the procedure time. We compared the primary and mid-
term outcome of DES implantation in the calciﬁed lesions
of hemodialysis patients using PTCRA (PTCRA group) to
those where DES was implanted without PTCRA (non-PTCRA
group).Primary end point
The primary endpoint was a composite of major adverse car-
diac and cerebrovascular events (death from cardiac causes,
myocardial infarction, ischemia-driven TLR, and cerebrovas-
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Nin which we could detect circular calciﬁcation or bulky calciﬁ-
onary artery. (B) Bulky calciﬁcation of left anterior descending
ular events) within the ﬁrst 12 months of follow-up. TLR
as deﬁned as revascularization for a stenosis within the
tented region or within 5mm of the distal or proximal edges
f the stent.
Successful stenting was deﬁned as a ﬁnal stenosis of less
han 50% of the vessel diameter after implantation of the
tudy stent. Treatment success was deﬁned as a ﬁnal stenosis
f less than 50% of the vessel diameter after any percuta-
eous intervention.
uantitative CAG
oronary angora’s were digitally recorded at baseline, post
rocedure, and at follow-up with an automated edge-
etection system (CAAS II, Pie Medical Imaging, Maastricht,
he Netherlands). The single projection in which a stenosis
ppeared to be most severe was used. A contrast-ﬁlled non-
apered catheter tip was used for calibration and reference
iameter was determined by interpolation. Quantitative
easurements included the diameter of the reference ves-
el, the minimum luminal diameter (MLD), and the extent
f diametric stenosis deﬁned as [(reference vessel diam-
ter−MLD)/reference vessel diameter]× 100. We deﬁned
SR as stenosis of at least 50% of the MLD in the stented area
nd within the margins 5mm proximal and distal to each
tent edge.
tatistical analysis
uantitative data are presented as mean± standard devi-
tion (SD) and the categorical data as frequencies
percentages). Continuous variables were compared using
he unpaired t-test. Binary variables were compared by
eans of the Fisher’s exact test. Statistical signiﬁcance was
eﬁned as p-value of less than 0.05. All statistical analyses
ere performed using JMP 5 software (SAS Institute, Cary,
C, USA).
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Table 1 Baseline patient characteristics.
Non-PTCRA (n = 28) PTCRA (n = 26) p-Value
Age (year) 66.2± 8.1 65.0± 10.4 0.65
Male (%) 78.6 76.9 0.89
Hypertension (%) 85.7 76.9 0.42
Hyperlipidemia (%) 39.3 30.1 0.52
Diabetes mellitus (%) 67.9 61.5 0.64
Smoking (%) 64.3 65.4 0.93
Hyperuricemia (%) 14.3 19.2 0.62
Family history of CAD (%) 17.9 26.9 0.43
Duration of hemodialysis (years) 6.7± 2.8 7.5± 3.1 0.40
Etiology of renal failure (%)
Diabetic nephropathy 64.2 61.5 0.83
CGN 18.5 22.7 0.72
Nephrosclerosis 14.3 11.5 0.77
Other 3.0 4.3 0.68
Baseline medical treatment (%)
Aspirin 100 100 —
Ticlopidine or clopidogrel 100 100 —
ACE-I or ARB 35.7 34.6 0.93
Beta blocker 28.6 30.8 0.86
Calcium blocker 39.3 42.3 0.82
Statin 60.7 61.5 0.95
PTCRA, percutaneous transluminal coronary rotational atherectomy; CAD, coronary artery disease; CGN, chronic glomerulonephritis;
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
Table 2 Lesion and procedure characteristics.
Non-PTCRA (n = 28) PTCRA (n = 26) p-Value
LAD (%) 57.1 61.5 0.75
LCX (%) 10.7 3.8 0.34
RCA (%) 32.1 34.6 0.85
Lesion length (mm) 26.3± 3.8 26.6± 7.9 0.88
Reference diameter (mm)
Pre-intervention 2.82± 0.30 2.87± 0.32 0.56
Post-intervention 2.81± 0.38 2.89± 0.44 0.59
MLD (mm)
Pre-intervention 0.38± 0.20 0.45± 0.21 0.68
Post-intervention 2.53± 0.34 2.76± 0.39 0.042
Diametric stenosis (%)
Pre-intervention 88.7± 6.9 84.0± 5.4 0.78
Post-intervention 11.5± 4.1 6.2± 2.2 <0.0001
Sirolimus-eluting stent (%) 53.6 53.8 0.98
Stent diameter (mm) 2.76± 0.40 3.04± 0.42 0.01
Number of stents 1.3 1.4 0.67
Final balloon diameter (mm) 2.96± 0.28 3.08± 0.38 0.22
Final dilatation pressure (atm) 16.5± 3.0 14.8± 2.5 0.024
Use of IVUS (%) 28.6 76.9 0.044
Final burr size (mm) — 1.61± 0.16 —
Burr/artery ratio — 0.58± 0.15 —
PTCRA, percutaneous transluminal coronary rotational atherectomy; LAD, left anterior descending coronary artery; LCX, left circumﬂex
coronary artery; RCA, right coronary artery; MLD, minimum lumen diameter; IVUS, intravascular ultrasound.
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Table 3 Clinical outcomes.
Non-PTCRA (n = 28) PTCRA (n = 26) p-Value
In-stent thrombosis (%) 7.1 0 0.31
Cardiac death (%) 0 3.8 0.37
Myocardial infarction (%) 7.1 0 0.31
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CCerebrovascular events (%) 0
TLR (%) 35.7
PTCRA, percutaneous transluminal coronary rotational atherectom
Results
Baseline and procedural characteristics
Baseline characteristics of the enrolled patients are shown in
Table 1. There were no signiﬁcant differences in the patient
characteristics between PTCRA group and non-PTCRA group.
The most common etiology of renal failure was diabetic
nephropathy in both groups, followed by chronic glomeru-
lonephritis, and nephrosclerosis. All of the patients received
dual antiplatelet therapy using aspirin 100mg per day, and
ticlopidine 200mg per day or clopidogrel 75mg per day dur-
ing the follow-up period.
Lesion characteristics and procedural characteristics are
shown in Table 2. Lesion characteristics were not signiﬁ-
cantly different between the two groups. Sirolimus-eluting
stents (Cypher, Cordis Corporation, Miami, FL, USA) were
used in 53.8% of the patients in the PTCRA group and 53.6%
of the patients in the non-PTCRA group (p = 0.73). Paclitaxel-
eluting stents (Taxus, Boston Scientiﬁc Corporation, San
t
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Figure 2 A case of acute thrombosis in the non-percutaneous tran
69-year-old patient with a 7-year history of hemodialysis because of
CAG showed a stenotic lesion with severe calciﬁcation in the right co
implanted without PTCRA. (C) Post dilatation was performed with a
dilated at the ﬁnal angiogram of percutaneous coronary interventio
emergent CAG showed acute thrombosis within the stent. .0 —
11.5 0.026
LR, target lesion revascularization.
iego, CA, USA) were used in the remaining 46% of the
atients in both groups.
Final balloon pressure was higher in the non-PTCRA group
han in the PTCRA group (16.5± 3.0 atm vs 14.8± 2.5 atm,
= 0.024). Although the reference diameter after percu-
aneous coronary intervention (PCI) was almost the same
or the two groups, MLD was larger (2.53± 0.34mm vs
.76± 0.39mm, p = 0.042) and percent diametric steno-
is was smaller (11.5± 4.1% vs 6.2± 2.2%, p < 0.0001)
n the PTCRA group than in the non-PTCRA group
Table 2).
linical outcomes
linical outcomes are shown in Table 3. Subacute in-stent
hrombosis with acute myocardial infarction occurred in two
atients in the non-PTCRA group. In both cases, in-stent
hrombosis occurred because of the underexpansion of the
ES (Fig. 2). Also, one patient in the PTCRA group died just
fter a failed PCI which did not achieve proper ﬂow. TLR
sluminal coronary rotational atherectomy (PTCRA) group. (A) A
diabetic nephropathy underwent coronary angiography (CAG).
ronary artery. (B) A paclitaxel-eluting stent (2.5 × 12 mm) was
maximum pressure of 22 atm. (D) The stent could not be fully
n. (E) The next day, the patient complained of chest pain, and
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Table 4 Angiographical outcomes at follow-up coronary angiography.
Non-PTCRA (n = 24) PTCRA (n = 18) p-Value
Reference diameter (mm) 2.60± 0.41 2.67± 0.40 0.61
MLD (mm) 1.51± 0.97 2.03± 0.98 0.11
Diametric stenosis (%) 40.9± 37.1 23.2± 35.7 0.14
Late loss (mm) 1.05± 1.02 0.61± 0.98 0.17
In-stent restenosis (%) 42.3 17.4 0.061
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Follow-up length (months) 7.9± 1.2
PTCRA, percutaneous transluminal coronary rotational atherectom
ate was lower in the PTCRA group than in the non-PTCRA
roup (11.5% vs 35.7%, p = 0.026).
ngiographic analysis
mong the 54 enrolled patients, 42 patients (18 in the PTCRA
roup, and 24 in the non-PTCRA group) underwent follow-
p CAG. Quantitative coronary angiography (QCA) ﬁndings
f the 42 patients are shown in Table 4. MLD was larger in
he PTCRA group than in the non-PTCRA group, although the
ifference was not statistically signiﬁcant. Percent diamet-
ic stenosis and late loss were also modestly lower in the
TCRA group than in the non-PTCRA group. The rates of ISR
nd target vessel failure were lower in the PTCRA group than
n the non-PTCRA group, although the differences were not
tatistically signiﬁcant.he effect of intravascular ultrasound
e analyzed the data of CAG and intravascular ultrasound
IVUS) classifying the population into four groups according
o the use of PTCRA and IVUS. The data are shown in Table 5.
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Table 5 Angiographical and IVUS data of the patients classifying
Non-PTCRA
IVUS (−) (n = 20) IVUS (+) (n = 8
Reference diameter (mm)
Pre-intervention 2.80 ± 0.29 2.87 ± 0.36
Post-intervention 2.81 ± 0.31 2.85 ± 0.36
At follow-upa 2.60 ± 0.40 2.61 ± 0.36
MLD (mm)
Pre-intervention 0.36 ± 0.21 0.45 ± 0.06
Post-intervention 2.51 ± 0.33 2.63 ± 0.37
At follow-upa 1.56 ± 0.55 1.41 ± 0.51
Diametric stenosis (%)
Pre-intervention 87.9 ± 4.9 90.9 ± 5.8
Post-intervention 11.3 ± 2.2 12.0 ± 4.4
At follow-upa 41.1 ± 27.8 42.4 ± 35.4
MLA post-intervention (mm2) — 5.53 ± 1.35
IVUS, intravascular ultrasound; PTCRA, percutaneous transluminal co
MLA, minimal lumen area.
a The number of patients who underwent follow-up coronary angiogr
non-PTCRA/IVUS (+): n = 7; non-PTCRA/IVUS (−): n = 4; non-PTCRA/IVU26.1 0.15
7.3± 1.4 0.63
LD, minimum lumen diameter.
he percent diametric stenosis at follow-up CAG in the non-
VUS group was not signiﬁcantly different from that in the
on-IVUS group regardless of the use of PTCRA. Therefore,
VUS use did not seem to affect the restenosis.
iscussion
he major ﬁnding of this study was that PTCRA and IVUS
elps adequate expansion of DES, thereby reducing the
ate of ISR and retenosis after implantation in the calciﬁed
esions of HD patients. Despite the signiﬁcant reduction of
estenosis by DES, several factors including diabetes, HD,
nd severe calciﬁcation have been reported to be high-risk
actors for restenosis after DES implantation [3—9]. In par-
icular, HD is a signiﬁcant risk factor for cardiac events,
nd the odds ratios of HD for restenosis or TLR after DES
mplantation was reported to be 3—6 in previous studies. But
here have not been reports regarding an effective strategy
o reduce restenosis after DES implantation in the calciﬁed
esions of HD patients. The mechanisms of restenosis after
ES implantation in HD patients may be multi-factorial. But
nderexpansion of the stents by severe calciﬁcation may be
mportant and affect the efﬁcacy of DES. In addition, higher
according to the use of IVUS.
p-Value PTCRA p-Value
) IVUS (−) (n = 6) IVUS (+) (n = 20)
0.57 2.81 ± 0.17 2.87 ± 0.41 0.78
0.80 2.79 ± 0.42 2.90 ± 0.53 0.65
0.97 2.55 ± 0.37 2.72 ± 0.29 0.97
0.26 0.46 ± 0.08 0.45 ± 0.21 0.91
0.41 2.72 ± 0.31 2.79 ± 0.36 0.68
0.53 2.06 ± 0.36 2.05 ± 0.99 0.0.96
0.18 83.3 ± 6.0 84.6 ± 6.2 0.66
0.58 4.8 ± 3.3 6.7 ± 2.1 0.11
0.92 23.8 ± 31.3 23.0 ± 26.7 0.95
— — 6.12 ± 1.71 —
ronary rotational atherectomy; MLD, minimum lumen diameter;
aphy in each group was as follows: non-PTCRA/IVUS (−): n = 17;
S (+): n = 14.
R[
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pressure, sometimes more than the rated pressure, was
needed to adequately expand DES in the non-PTCRA group
than in the PTCRA group. Such high pressure may induce
stent fracture and detachment of polymer coating from the
struts. Debulking of calciﬁcation by PTCRA should enable
an adequate expansion of the stents with low pressure, and
avoid the fracture of the struts.
In our study, the ratio of IVUS use was different between
the non-PTCRA group and the PTCRA group. But the per-
cent diametric stenosis at follow-up CAG in the non-IVUS
group was not signiﬁcantly different from that in the IVUS
group regardless of the use of PTCRA. Therefore, IVUS use
did not seem to affect restenosis. Several studies reported
that IVUS is useful to achieve a good expansion of the stent
and result in a favorable long-term outcome of BMS implan-
tation [10,11]. But the inﬂuence of IVUS on DES implantation
is not yet clear. According to several studies, long-term
outcome of DES implantation with angiographical guidance
seems good enough [1,2]. We think the better outcomes in
the PTCRA group are due to the effect of PTCRA itself rather
than IVUS.
The rates of ISR, target vessel failure, and TLR after DES
implantation for HD patients using PTCRA and IVUS in our
study are still higher than that for non-HD patients reported
by previous studies. Moreover, cardiac events for new lesions
often occur in HD patients. Much more investigation about
the mechanisms of in-stent restenosis in HD patients and
information as to how to prevent cardiac events after PCI
is necessary. But target vessel failure due to new stenotic
lesions remains a problem of PCI for HD patients.
Most of the patients in the non-PTCRA group of our study
underwent PCI in the ﬁrst few years since we began to use
DES in our hospital. We did not perform PTCRA in those
patients because we did not expect ISR to occur so fre-
quently after DES implantation. But the restenosis rate of
the DES implantation without PTCRA in the calciﬁed lesions
of HD patients was almost the same as that of lesions that
used BMS. Thereafter, we tried to perform PTCRA and IVUS
based on the idea that PTCRA may improve the long-term
outcome of DES implantation in the calciﬁed lesions of HD
patients. Thus, the lesion characteristics are very similar
between the PTCRA group and the non-PTCRA group, and
there is unlikely to be any selection bias.
Study limitation
This was a retrospective study with a small number of
patients. A randomized study with a larger patient popula-
tion will be necessary to conﬁrm the results. Moreover, the
longer term outcome of DES implantation in the calciﬁed
lesions of HD patients using PTCRA should be clariﬁed.Conclusion
PTCRA may be useful for improving the primary- and mid-
term outcomes of DES implantation in the calciﬁed lesions
of HD patients.237
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